The
Life sciences industry plays a significant and pivotal role in protecting public health which involves various activities right from advancing cancer treatments to discovering new vaccines to making breakthroughs in stem cell research. This leads to the creation of huge societal value for Life Sciences organizations since their products, as well as purposes, contribute towards medical as well as the practical progress.
ESG (Environmental, social and corporate governance) analysis is gaining huge popularity as a major phase in the investing process. It not only allows the investors in applying a comparative framework which is used to measure an organization’s social responsibility against their peers in the same industry but also Investors in analyzing a potential investee’s environmental concerns, & corporate ethos in order to obtain a better understanding of the non-financial factors at play within an organization.
While the methodology is positioned in such a way that it is centered around the concept where investment is as successful as the social responsibility of the investee’s business model & the intrinsic sustainability. However, with no sustainable development, the investee will degrade over time, which will lead to the loss of investor capital. Therefore, by aligning the financial success of the organization with conscientious activity, the enterprise is incentivized to make sustainable development activities that in turn lead to benefit society, make a strong and mitigate an investor’s risk. Hence, investing such a tactic into life sciences helps in a more comprehensive view of an organization’s outlook and helps in creating a clear impetus for enterprises to work for a more sustainable future. The life science-specific ESG (Environmental, social and corporate governance) method reduces into 3 fundamental steps that include analyzing sustainability, screening ethics & connection maintenance.
Innovation & development
Infosys, recently made an announcement that it
has launched Infosys Springboard for accelerating progress on its ESG (Environmental, social and corporate governance) goal in order to expand digital reskilling initiatives to ten million plus people by the year 2025. Infosys Springboard renders a curriculum-rich virtual platform, which helps in delivering corporate-learner collaboration for students from Class VI to lifelong learners, that range from school & college students to professionals as well as adults, as part of Infosys CSR.
“The pandemic has underscored the urgent need for accessible instruments of digital learning for people from all walks of life. Infosys, for decades, has already been working to strengthen digital capabilities within our own workforce, our clients, students, and the communities we engage with. Infosys Springboard is a significant investment to help deliver on our ongoing ESG commitment to bridge the digital divide as we move into the future,” said, Nilanjan Roy, Chief Financial Officer at Infosys.
Thirumala Arohi, Senior Vice President and Head - Education, Training, and Assessment at Infosys, said, “Students and educators need digital curricula and platforms that are more than just hand-me-downs from corporates to truly serve their needs. Parents and guardians, on the other hand, need the assurance that the learning prepares their wards adequately for the future. NGOs and support groups need to extend the learning and make it more inclusive across the strata of our society. Infosys Springboard creates a framework that addresses all of their pressing concerns.”
Sustainability analysis
This analysis is designed in such a way that it helps in investigating sector-specific ESG (Environmental, social and corporate governance) metrics. And in the life sciences segment, the corporate governance, innovative capability, climate impact, and accessibility and product development pipeline, for all are the major areas of focus.
Innovative capability
An investor could gain insights into an investee’s ability to follow the needs of the times by analyzing the innovative capability of an organization. The major examples of highly capable investments include organizations that are working with innovative pipelines in search of cutting-edge therapies.
Product development pipeline & clinical trials
The fate of any life sciences organization is mainly based on the outcome of their clinical traits. Therefore, any lack of motivation to share data, dishonest communication of testing results, or failure to adhere to clinical protocols will lead to a fail point on the ESG (Environmental, social and corporate governance) scale. Hence, what displays the level of scientific expertise in a life science study is clear as well as transparent study protocols performed by experienced clinical investigators. What helps in retaining a positive outlook for an organization is development pipelines, positive phase II data, and active pursuit of large-scale studies
